Clinical Trials: Mantle Cell Lymphoma

Huntsville : Clearview Cancer Institute

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit Updated

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Tucson : Arizona Cancer Center Updated

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine

Tucson : Hematology Oncology Physicans Extenders Group Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Little Rock : University of Arkansas for Medical Sciences

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Little Rock : University of Arkansas for Medical Sciences Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Duarte : City of Hope Updated

A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma post Autologous Hematopoietic Cell Transplantation

View More »

Fullerton : St. Jude Heritage Medical Group Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Loma Linda : Loma Linda University Medical Center

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Los Angeles : Tower Cancer Research Foundation

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Los Angeles : UCLA

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Palm Springs : Comprehensive Cancer Center Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Palo Alto : Stanford Cancer Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Stanford : Stanford University School of Medicine

TLR8 Agonist VTX-2337 in Combo With Local Radiation in Low-Grade B-cell Lymphomas

Aurora : Investigational Site Number 840004

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

Aurora : University of Colorado Cancer Center Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

New Britain : The Hospital of Central Connecticut Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Boca Raton : Boca Raton Community Hospital, Inc. - Center for Hematology-Oncology

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Brooksville : Pasco Hernando Oncology Associates

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Ft. Lauderdale : Broward General Medical Center

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Hollywood : Memorial Cancer Institute Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Orlando : MD Anderson Cancer Center Orlando, Orlando Regional Healthcare

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

View More »

Orlando : Cancer Centers of Florida Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

The Villages : Lake County Oncology and Hematology

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Atlanta : Emory University Winship Cancer Institute

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Augusta : Georgia Health Sciences University

Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

Augusta : Investigational Site Number 840006

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

Columbus : John B Amos Cancer Center Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Chicago : Northwestern University

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Maywood : Loyola University Medical Center

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Indianapolis : Indiana University Cancer Center

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Waterloo : Cedar Valley Medical Specialists Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Wichita : Cancer Center of Kansas Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Lexington : University of Kentucky Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Shreveport : LSU Health Sciences Center - Shreveport Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Baltimore : Sinai Hospital - Alvin & Lois Lapidus Cancer Institute

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Bethesda : Center for Cancer and Blood Disorders

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Boston : Beth Israel Deaconess Medical Center

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Boston : Dana-Farber Cancer Institute

Oral Clofarabine for Relapsed/Refractory Indolent B-cell NHL and Mantle Cell Lymphoma

Boston : Massachusetts General Hospital

Oral Clofarabine for Relapsed/Refractory Indolent B-cell NHL and Mantle Cell Lymphoma

Detroit : Karmanos Cancer Institute

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Rochester : Mayo Clinic Updated

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Rochester : Mayo Clinic

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Columbia : Missouri Cancer Associates Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

St Louis : Washington University School of Medicine

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

St. Louis : Washington University School of Medicine

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Omaha : Univeristy of Nebraska Medical Center

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Hackensack : Hackensack University Medical Center

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Hackensack : Research Site

AMG 319 Lymphoid Malignancy FIH

Hackensack : Hackensack University Medical Center

Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma

Albuquerque : UNM Cancer Center/New Mexico Cancer Care Alliance Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

New Hyde Park : Long Island Jewish Medical Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

New York : Weill Cornell Medical College

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

New York : Memorial Sloan-Kettering Cancer Center

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

New York : Memorial Sloan-Kettering Cancer Center

Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

New York : Weill Medical College of Cornell

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

View More »

New York : Weill Cornell Medical College

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Rochester : University of Rochester Cancer Center, James P. Wilmot Cancer Center

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Rochester : Interlakes Foundation, Inc Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Syracuse : SUNY Upstate / Upstate Medical University Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Charlotte : Presbyterian Hospital

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Durham : Research Site

AMG 319 Lymphoid Malignancy FIH

Bismarck : Legacy Pharma Research

Newly Diagnosed Mantle Cell Lymphoma who are not eligible for a bone marrow transplant.

Springfield : Willamette Valley Cancer Center Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Springfield : Willamette Valley Cancer Institute and Research Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Danville : Geisinger Medical Center Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Philadelphia : Temple University School of Medicine

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Philadelphia : Pennsylvania Oncology Hematology Associates, Inc. Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Pittsburg : UPMC, Hillman Cancer Center

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Charleston : Investigational Site Number 840002

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

Charleston : Charleston Hematology Oncology, PA Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Hilton Head Island : South Carolina Cancer Specialists

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Chattanooga : Chattanooga Oncology Hematology Associates

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Memphis : University of Tennessee, Boston Baskin Cancer Group, PLC

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Nashville : Sarah Cannon Research Institute Updated

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Nashville : Tennessee Oncology, PLLC

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Nashville : Sarah Cannon Research Institute

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Dallas : Mary Crowley Cancer Research Centers - Medical City Updated

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Fort Worth : Texas Oncology, P.A. Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Houston : UT MD Anderson Cancer Center

Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma

Houston : UT MD Anderson Cancer Center

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

Houston : MD Anderson Cancer

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

View More »

San Antonio : Cancer Care Center of South Texas Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Charlottesville : University of Virginia Health System Updated

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Charlottesville : University of Virginia

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Norfolk : Virginia Oncology Associates Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Seattle : Seattle Cancer Care Alliance

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Spokane : Cancer Care Northwest-South Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Vancouver : Northwest Cancer Specialists, PC Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Yakima : North Star Lodge Cancer Center

Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Morgantown : West Virginia University - Clinical Trials Research Unit

C18083-3064/NL/MN - An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

View More »

Morgantown : West Virginia University School of Medicine Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Madison : University of Wisconsin

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Adelaide : Royal Adelaide Hospital Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Innsbruck : Univ Klinik Innsbruck

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Salzburg : St Johanns Spital - Landesklinik fuer Innere Medizin III

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Wien : Akh Univ Kliniken Wien

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Brugge : AZ St Jan

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Gent : Universitair Ziekenhuis Gent

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Leuven : Universitair Ziekenhuis Leuven

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Ottawa : Ottawa Hospital - General Campus Updated

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Bogotá : Hospital Universitario San Ignacio

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Pereira : Oncologos del Occidente S.A

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Brno-Bohunice : FN Brno

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Hradec Králové : Fakultni nemocnice Hradec Kralove

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Praha : Charles University General Hospital

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Copenhagen : Rigshospitalet, Department of Hematology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Helsinki : Helsinki University Central Hospital

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Amiens : CHU d'Amiens - Hôpital Sud

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Bordeaux : Institut Bergonie

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Creteil Cedex : Hôpital Henri Mondor

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Grenoble : Valerie ROLLAND NEYRET

Study of Mantle Cell Lymphoma Treatment by RiBVD

Mulhouse Cedex : CHU de Mulhouse - Hopital Emile Muller

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

View More »

Nantes Cedex 1, : CHRU - Hotel Dieu, Hématologie

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Paris : Institut Curie

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Paris : Hôpital Cochin

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Reims : CHU de Reims - Hôpital Robert Debré

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Rennes Cedex : CHU de Rennes Hôpital de Pontchaillou

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Saint Priest en Jarez : Institut de Cancérologie de la Loire

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Strasbourg : ChU Hautepierre

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Freiburg : Universitätsklinikum Freiburg - Medizinische Klinik

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Göttingen : UKG Universitätsklinikum Göttingen

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Mainz : Universitätsmedizin Mainz

Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

Ulm : Universitätsklinikum Ulm

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Wuerzburg : Universitaetsklinikum Wuerzburg

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Budapest :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Debrecen :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Debrecen : Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Gyor :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Gyor : Petz Aladar Megyei Oktato Korhaz

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

View More »

Kaposvar :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Kaposvar : Kaposi Mor Megyei Korhaz

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Miskolc :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Szeged :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Zalaegerszeg :

A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.

Haifa : Rambam Health Care Campus

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Jerusalem : Hadassah Universtiy Hospital - Ein Kerem

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Petah-Tikva : Rabin Medical Center

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Ramat Gan : Chaim Sheba Medical Center

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Napoli : Università Federico II di Napoli Nuovo Policlinico

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Pescara : Ospedale Civile dello Spirito Santo

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Rome : Università Cattolica del Sacro Cuore

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Oslo : Norwegian Radium Hospital

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Stavanger : University Hospital of Stavanger, Department of Haematology and Oncology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Warszawa : Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie w Warszawie

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Wrocław : S.P. Szpital Kliniczny Nr1, Klinika Hematologii Nowotworów Krwi i Transplantacji Szpiku, ul. Pasteura

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

San Juan : Hospital Espanol Auxilio de Puerto Rico

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

St. Petersburg : Federal State Institution "Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies named after V.A. Almazov"

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

St. Petersburg : St. Petersburg Research Institute of Hematology and Blood Transfusion

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Volgograd : State Healthcare Institution "Volgograd Regional Clinical OncologyDispensary #1"

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Singapore : Singapore General Hospital

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Elche- Alicante : HGU de Elche

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Llobregat : Institut Catalá d' Oncología L'Hospitalet

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Salamanca : Hospital Univ de Salamanca

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Valencia : Hospital Universitario La Fe Neurology

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Göteborg : Sahlgrenska University Hospital, Department of Hematology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Linköping : University Hospital Linköping, Department of Hematology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Luleå : Sunderbyn Hospital, Department of Medicine

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Lund : University Hospital Lund, Department of Oncology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Stockholm : Karolinska University Hospital, Department of Hematology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

View More »

Sundsvall : Sundsvall Hospital, Department of Medicine

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Umeå : University Hospital of Norrland, Department of Oncology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Uppsala : Uppsala University Hospital, Department of Oncology

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Ankara : Gazi University Medical Faculty

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Ankara : Ankara University Medical Faculty

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Istanbul : Istanbul University Istanbul Medical Faculty

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Dorset, : The Royal Bournemouth Hospital

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

London : King's College Hospital

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

London : University College London

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Manchester : Christie Hospital

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Manchester : The Christie NHS Foundation

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

View More »

Newcastle upon Tyne : University of Newcastle Upon Tyne, NHS Foundation Trust

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Plymouth : Derriford Hospital

A Study to Determine the Efficacy of Lenalidomide Versus Investigator Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Truro : Royal Cornwall Hospital

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial